Zidovudine therapy is associated with an increased capacity of phytohemagglutinin-stimulated cells to express interleukin-2 receptors. Pittsburgh AIDS Clinical Trial Unit

AIDS. 1991 May;5(5):491-6. doi: 10.1097/00002030-199105000-00003.

Abstract

Zidovudine therapy of AIDS patients has been shown to cause only transient improvements in the numbers of circulating CD4+ cells and the in vitro functional activities of cultured lymphocytes. The present studies were undertaken to determine whether prolonged zidovudine therapy enhanced reactivity in two sensitive assays of T-cell function: the ability of phytohemagglutinin (PHA)-stimulated cells to form T-cell colonies and their capacity to express receptors for the growth factor interleukin-2 (IL-2). Treated patients, studied over periods of 20-60 weeks, showed no improvement in colony formation at any time interval, even in plates supplemented with exogenous IL-2. However, mitogen-stimulated T lymphocytes showed a significant increase in the capacity to express IL-2 receptors (CD25). This enhanced expression resulted primarily from activation of the CD8+ cell subset.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Colony-Forming Units Assay
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV-1 / drug effects
  • Humans
  • Lymphocyte Activation / drug effects
  • Male
  • Phytohemagglutinins / pharmacology
  • Receptors, Interleukin-2 / analysis
  • Receptors, Interleukin-2 / biosynthesis*
  • Receptors, Interleukin-2 / drug effects
  • T-Lymphocyte Subsets / drug effects*
  • T-Lymphocyte Subsets / immunology
  • Zidovudine / therapeutic use*

Substances

  • Phytohemagglutinins
  • Receptors, Interleukin-2
  • Zidovudine